Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine for Working Memory in Post-COVID-19
NCT05274477Phase 2Terminated
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalfampridine in post-COVID-19 condition (PCC). Started Jun 2022; status: terminated.
02
Drugs
dalfampridine
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05274477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274477.